Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Correlation between tumor burden and anticomplementary activity in sera from cancer patients

  • 9 Accesses

  • 1 Citations

Summary

A total of 739 sera from cancer patients, noncancer patients and normal donors were analyzed for anticomplementary (AC) activity by the complement consumption method. The results were correlated with clinical stage and tumor burden. The incidence of AC activity in cancer and noncancer patients' sera was 53% (233/439) and 67% (100/150), respectively, as against 14% (20/140) in normal donors' sera. Among cancer patients, this incidence was lowest (42%) for melanoma sera and highest (65%) for lung carcinoma sera. With the exception of sarcoma sera, the incidence of AC activity did not differ significantly with clinical Stages I, II, or III. Sera from Stages II and III sarcoma patients had a significantly higher incidence of AC activity (73% and 63%, respectively) than Stage I (38%). There appeared to be a higher incidence of AC activity in sera of cancer patients with 1–100 g tumor burden than in those from patients with tumors greater than 100 g or less than 1 g. Follow-up of cancer patients with no evidence of disease or minimal tumor burden revealed that 42% (18/43) whose sera were AC-positive had tumor recurrence within 3 months and 90% (57/63) whose sera were AC-negative had no detectable tumor recurrence up to at least 6 months after the serum analysis.

This is a preview of subscription content, log in to check access.

References

  1. Baldwin, R. W., Bowen, J. G., Price, M. R.: Detection of circulating hepatoma, D23 antigen and immune complexes in tumor bearer serum. Br. J. Cancer 28, 1624 (1973)

  2. Bland, K. I., Ludwig, F. J., Heishman, A. F., Safian, R. D., Pfaff, W. W., Cusumano, C. L.: Method of detection of circulating immune complexes. Surg. Forum 25, 111–112 (1974)

  3. Cochrane, C. G., Koffler, D.: Immune complex disease in experimental animals and man. Adv. Immunol. 16, 185–264 (1973)

  4. Currie, G. A.: The role of circulating antigen as an inhibitor of tumor immunity in man. Br. J. Cancer 28, 153–161 (1973)

  5. Dixon, W. J., Massey, J. R.: Introduction to statistical analysis, 3rd ed. New York: McGraw-Hill 1969

  6. Gupta, R. K., Morton, D. L.: Tumor-related immune complexes in sera from melanoma patients. Fed. Proc. 37, 1595 (1978)

  7. Heimer, R., Klein, G.: Circulating immune complexes in sera of patient's with Burkitt's lymphoma and nasopharyngeal carcinoma. Int. J. Cancer 18, 310–316 (1976)

  8. Hoffken, K., Meredith, I. D., Robins, R. A., Baldwin, R. W., Davies, C. J., Blaney, R. W.: Circulating immune complexes in patients with breast cancer. Br. Med. J. 1977 2, 218–220

  9. Johnson, A. S., Mowberay, J. F., Porter, K. A.: Detection of circulating immune complexes in pathological human sera. Lancet 1975 1, 762–765

  10. Jose, D. G., Seshaderi, R.: Circulating immune complexes in human neuroblastoma: Direct assay and role in blocking the specific cellular immunity. Int. J. Cancer 13, 824–838 (1974)

  11. Mukojima, T., Gunven, P., Klein, G.: Circulating antigen—antibody complexes associated with Epstein virus in recurrent Burkitt's lymphoma. J. Natl. Cancer Inst. 51, 1319–1321 (1973)

  12. Oldstone, M. B. A.: Immune complexes in cancer: Demonstration of complexes in mice bearing neuroblastomas. J. Natl. Cancer Inst. 54, 223–228 (1973)

  13. Rossen, R. D., Reisberg, M. A., Hersch, E. M., Gutterman, J. U.: The Clq binding test for soluble immune complexes: Clinical correlations obtained in patients with cancer. J. Natl. Cancer Inst. 58, 1205–1215 (1977)

  14. Samayoa, E. A., McDuffie, F. C., Nelson, A. M., Go, V. L. W., Luthra, S. S., Brumfield, H. W.: Immunoglobulin complexes in serum of patients with malignancy. Int. J. Cancer 19, 12–17 (1977)

  15. Sjogren, H. O., Hellstrom, I., Bansal, S. C., Warner, J. A., Hellstrom, K. E.: Elution of ‘blocking factors’ from human tumors capable of abrogating tumor-cell destruction by specifically immune lymphocytes. Int. J. Cancer 9, 274–283 (1972)

  16. Theofilopoulos, A. N., Wilson, C. B., Dixon, F. J.: Raji-cell radioimmunoassay for detecting immune complexes in human sera. J. Clin. Invest. 57, 169–182 (1976)

  17. Theofilopoulos, A. N., Andrews, B. S., Urist, M. M., Morton, D. L., Dixon, F. J.: The nature of immune complexes in a human cancer serum. J. Immunol. 119, 657–663 (1977)

  18. Thompson, D. M. P., Steel, K., Alexander, B.: Presence of tumor-specific membrane antigen in the serum of rats with chemically induced sarcomata. Br. J. Cancer 27, 27–34 (1973)

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gupta, R.K., Golub, S.H. & Morton, D.L. Correlation between tumor burden and anticomplementary activity in sera from cancer patients. Cancer Immunol Immunother 6, 63–71 (1979). https://doi.org/10.1007/BF00200134

Download citation

Keywords

  • Cancer Patient
  • Melanoma
  • Sarcoma
  • Tumor Recurrence
  • Clinical Stage